Sandoz Group AGSDZXF 18 3-Year ROIIC % is 1.33 as of Dec. 2025, which is at its 10-year median of 1.33. GuruFocus rates SDZXF with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 941 Drug Manufacturers companies, Sandoz Group AG ranks worse than 54.84% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sandoz Group AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1.33%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sandoz Group AG's 3-Year ROIIC % or its related term are showing as below:
SDZXF's 3-Year ROIIC % is ranked worse than 54.84% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs SDZXF: 1.33
Sandoz Group AG (OTCPK:SDZXF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sandoz Group AG 3-Year ROIIC % Related Terms
Sandoz Group AG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SDZXF vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's 3-Year ROIIC % falls into.
Sandoz Group AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 1079.01 (Dec. 2025) - 955.6407 (Dec. 2022) )
/
( 17828 (Dec. 2025) - 17706 (Dec. 2022) )
=
123.3693
/
122
=
101.12%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sandoz Group AG (SDZXF) has a 3-Year ROIIC % of 1.33 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sandoz Group AG and its competitors. This is near median its historical median of 1.33. Over the past decade, Sandoz Group AG's 3-Year ROIIC % has ranged from 1.33 to 1.33. According to the industry distribution chart, Sandoz Group AG ranks #516 out of 941 companies in the Drug Manufacturers industry, placing it in the top 54.8%.
Is Sandoz Group AG's 3-Year ROIIC % too high?
Sandoz Group AG's current 3-Year ROIIC % of 1.33 is near median its 10-year median of 1.33. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 1.33. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Sandoz Group AG's value of 1.33 is 64.4% below this industry median. Based on the distribution chart, Sandoz Group AG ranks #516 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #516 out of 941 companies for 3-Year ROIIC %. This places Sandoz Group AG in the lower half of its industry. The industry median 3-Year ROIIC % is 3.74. Sandoz Group AG's value of 1.33 is 64.4% below this benchmark. Historically, Sandoz Group AG's own 3-Year ROIIC % has ranged from 1.33 to 1.33 over the past decade. While the company's 10-year median is 1.33 vs. the industry median of 3.74, Sandoz Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current 3-Year ROIIC % of 1.33 is 64.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current 3-Year ROIIC % is 1.33, which is near median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current 3-Year ROIIC % of 1.33. The current 3-Year ROIIC % is 1.33, which is near median its 10-year median of 1.33 and 64.4% below the Drug Manufacturers industry median of 3.74. Sandoz Group AG's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current 3-Year ROIIC % is 1.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
18GF Score
Get the complete analysis for SDZXF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDZXF has been successfully added to your 